Mesenchymal stem cells derived from adipose tissue are not affected by renal disease.
Mesenchymal stem cells are a potential therapeutic agent in renal disease and kidney transplantation. Autologous cell use in kidney transplantation is preferred to avoid anti-HLA reactivity; however, the influence of renal disease on mesenchymal stem cells is unknown. To investigate the feasibility of autologous cell therapy in patients with renal disease, we isolated these cells from subcutaneous adipose tissue of healthy controls and patients with renal disease and compared them phenotypically and functionally. The mesenchymal stem cells from both groups showed similar morphology and differentiation capacity, and were both over 90% positive for CD73, CD105, and CD166, and negative for CD31 and CD45. They demonstrated comparable population doubling times, rates of apoptosis, and were both capable of inhibiting allo-antigen- and anti-CD3/CD28-activated peripheral blood mononuclear cell proliferation. In response to immune activation they both increased the expression of pro-inflammatory and anti-inflammatory factors. These mesenchymal stem cells were genetically stable after extensive expansion and, importantly, were not affected by uremic serum. Thus, mesenchymal stem cells of patients with renal disease have similar characteristics and functionality as those from healthy controls. Hence, our results indicate the feasibility of their use in autologous cell therapy in patients with renal disease.
Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. m.vanrhijn@erasmusmc.nl
Marieke
M
Roemeling-van Rhijn
Marlies E J
ME
Reinders
Annelies
A
de Klein
Hannie
H
Douben
Sander S
SS
Korevaar
Fane K F
FK
Mensah
Frank J M F
FJ
Dor
Jan N M
JN
IJzermans
Michiel G H
MG
Betjes
Carla C
CC
Baan
Willem
W
Weimar
Martin J
MJ
Hoogduijn
D015720:5'-Nucleotidase / Q000378:metabolism; D000273:Adipose Tissue / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D017209:Apoptosis; D015415:Biomarkers / Q000378:metabolism; D018106:CD28 Antigens / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D016022:Case-Control Studies; D015816:Cell Adhesion Molecules, Neuronal / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D002469:Cell Separation / Q000379:methods; D048430:Cell Shape; D002478:Cells, Cultured; D018920:Coculture Techniques; D000071063:Endoglin; D005260:Female; D005326:Fetal Proteins / Q000378:metabolism; D005434:Flow Cytometry; D058851:GPI-Linked Proteins / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D018836:Inflammation Mediators / Q000378:metabolism; D007674:Kidney Diseases / Q000097:blood / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D017493:Leukocyte Common Antigens / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D010641:Phenotype; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism; D013997:Time Factors; D014182:Transplantation, Autologous; D014511:Uremia / Q000097:blood / Q000276:immunology; D020410:Activated-Leukocyte Cell Adhesion Molecule
D015720:5'-Nucleotidase; D015703:Antigens, CD; D015415:Biomarkers; D018106:CD28 Antigens; D017252:CD3 Complex; D015816:Cell Adhesion Molecules, Neuronal; D000071063:Endoglin; D005326:Fetal Proteins; D058851:GPI-Linked Proteins; D018836:Inflammation Mediators; D017493:Leukocyte Common Antigens; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011956:Receptors, Cell Surface; C105613:ALCAM protein, human; D020410:Activated-Leukocyte Cell Adhesion Molecule; C064206:ENG protein, human; C516769:PTPRC protein, human; C548241:NT5E protein, human